Bipolar Depression Ketamine Trial: One Patient's Experience

A Trial Patient Says Ketamine Changed His Life With Bipolar Depression

A patient enrolled in a clinical trial testing ketamine for bipolar depression told CP24, a Toronto-based news outlet, that the treatment changed his life, according to a report published September 2, 2026. The report is a personal account rather than a study result: it does not include trial data, dosing details, the number of participants, or outcome measures, and CP24's description of the story does not name the sponsoring institution or the phase of the trial.

That distinction matters for anyone researching ketamine as an option for bipolar depression. Bipolar depression is the depressive phase of bipolar disorder, a mental health condition marked by cycling episodes of depression and mania or hypomania. It is treated differently from major depressive disorder because standard antidepressants can trigger a manic episode in people with bipolar disorder. That risk is a central reason ketamine research in bipolar depression has moved more cautiously and with smaller patient pools than ketamine research in unipolar, treatment-resistant depression.

Why Bipolar Depression Trials Look Different From Standard Ketamine Studies

Most of the ketamine and esketamine evidence base that shaped current clinical use comes from trials in unipolar treatment-resistant depression. Esketamine, sold under the brand name Spravato, is the only ketamine-related treatment approved by the U.S. Food and Drug Administration, and that approval covers treatment-resistant depression and depressive symptoms in adults with major depressive disorder who have suicidal ideation, not bipolar depression specifically. Use in bipolar depression is generally off-label or investigational, meaning it happens either in a research trial like the one CP24 describes or in a clinic prescribing outside the approved indication.

Researchers who study ketamine in bipolar disorder typically pair it with an existing mood stabilizer, such as lithium or valproate, precisely because of the manic-switch risk. A patient's report that the treatment changed his life is a meaningful personal outcome, but it does not tell readers whether that result held across the trial's full patient group, whether any participants experienced hypomania or mania during treatment, or how the effect compared to a placebo arm. Clinical trials exist to answer those questions, and results are usually reported months or years after enrollment closes, through peer-reviewed publication or a sponsor's data release rather than through a single patient interview.

What Bipolar Patients Should Ask Before Pursuing Ketamine Treatment

Readers weighing ketamine for bipolar depression in 2026 should start by separating three distinct paths: enrolling in a registered clinical trial, receiving FDA-approved esketamine for a qualifying depressive diagnosis, or seeking off-label IV or intramuscular ketamine at a private clinic. Each path has different oversight. Registered trials, listed on public registries such as ClinicalTrials.gov, include a defined protocol, safety monitoring, and an institutional review board overseeing patient safety. Esketamine treatment happens under the FDA's Risk Evaluation and Mitigation Strategy, which requires in-office administration and a two-hour monitoring period. Off-label ketamine clinics vary widely in how closely they screen for bipolar disorder history and how they coordinate with a patient's existing psychiatric care.

For bipolar patients specifically, the practical checklist is short but important. Ask whether the provider or trial screens for bipolar disorder before treatment, since a misdiagnosed or undisclosed bipolar history is one of the scenarios most likely to produce a manic reaction to antidepressant-like treatments. Ask how mood is monitored in the days after each dose, not just during the infusion itself, since a manic switch can emerge after the appointment ends. And ask how the treatment integrates with an existing mood stabilizer rather than replacing it. A treatment described as life-changing by one participant is worth watching for published results, but it is not yet grounds to change an existing treatment plan without a conversation with the psychiatrist managing that plan.

Source: CP24, September 2, 2026. This piece is analysis based on the published title and description of that report, not independent verification of the trial itself.